Clinicopathological and molecular predictors of [¹⁸F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.

ABSTRACT:

Background

The PHERGain study (NCT03161353) is assessing early metabolic responses to neoadjuvant treatment with trastuzumab-pertuzumab and chemotherapy de-escalation using a [¹⁸Fluorine]fluorodeoxyglucose-positron emission tomography ([¹⁸F]FDG-PET) and a pathological complete response-adapted strategy in HER2-positive (HER2+) early breast cancer (EBC). Herein, we present RESPONSE, a PHERGain substudy, where clinicopathological and molecular predictors of [¹⁸F]FDG-PET disease detection were evaluated.

Methods

A total of 500 patients with HER2 + EBC screened in the PHERGain trial with a tumor size > 1.5 cm by magnetic resonance imaging (MRI) were included in the RESPONSE substudy. PET[-] criteria entailed the absence of  ≥ 1 breast lesion with

SUBMITTER: Llombart-Cussac A 

PROVIDER: S-EPMC11224085 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature